Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096601 | 1.00 | KMT2A (0.66) | KMT2AL3MBTL1DRD2KDM4DMEN1 | |
| SCHEMBL29725634 | 0.84 | KMT2A (0.72) | KMT2AL3MBTL1MEN1OPRK1 | |
| SCHEMBL1851171 | 0.84 | KMT2A (0.91) | KMT2AL3MBTL1MEN1OPRK1 | |
| SCHEMBL2612633 | 0.82 | KMT2A (0.66) | KMT2AL3MBTL1MEN1OPRK1 | |
| SCHEMBL2330939 | 0.81 | RORC (0.46) | KMT2AL3MBTL1DRD2KDM4DMEN1 | |
| SCHEMBL2097985 | 0.80 | KDM4D (0.46) | KMT2AL3MBTL1DRD2KDM4DKCNA3 | |
| SCHEMBL2097983 | 0.80 | KDM4D (0.46) | KMT2AL3MBTL1DRD2KDM4DKCNA3 | |
| SCHEMBL4794886 | 0.79 | L3MBTL1 (1.00) | KMT2AL3MBTL1DRD2OPRK1 | |
| SCHEMBL20967988 | 0.79 | L3MBTL1 (1.00) | KMT2AL3MBTL1DRD2OPRK1 | |
| SCHEMBL29410965 | 0.79 | L3MBTL1 (1.00) | KMT2AL3MBTL1DRD2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163771-B2 | 11 β-HSD1 modulators | EXELIXIS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | EXELIXIS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | HSD11B1, HSD11B2, HSD3B1 | KMT2A 2538/4885L3MBTL1 2364/4885DRD2 1690/4885 |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | HSD11B1, HSD11B2, HSD3B1 | KMT2A 1907/4885L3MBTL1 2934/4885DRD2 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.